Although arginine consumer pegylated arginine deiminase (ADI-PEG20) has shown significant efficacy in vivo, in vitro, and in phase I clinical trials in ASS1-expressing deficient GBM, it had no significant effect on ASS1-positive GBM. Here, ASS1 is linked to glioblastoma.